Anne M. Rompalo, MD

CRS:

JHU

Role:

Investigators

Position:

HPTN Site Leader

Email:

arompalo@jhmi.edu

Anne M. Rompalo, M.D., Sc.M.  Dr. Rompalo is a Professor of Medicine and Gynecology at the Johns Hopkins University School of Medicine (JHUSOM), with joint appointments in Epidemiology, International Health and Population, Family and Reproductive Health at the Johns Hopkins Bloomberg School of Public Health.  She is Medical Director of the CDC-sponsored Sexually Transmitted Diseases (STD)/HIV Prevention Training Center at Johns Hopkins (PTC), and has previously been Acting Medical Director of the Baltimore City Health Departments STD Clinics and Medical Director of the Office of Population Affairs Male Training Center.  She has over 15 years of experience as the Medical Director of the STD/HIV PTC, and has been a key investigator on several studies focused on the natural history of HIV among women including the HERS (HIV Epidemiology Research Study) and HIV prevention among U.S. women at high risk for infection, HPTN 064 trial. 

  • Investigator of Record, HPTN 064
  • Investigator of Record, HPTN 083

Categories

Leadership Committees
CRS
Roles

Clinical Trials

Impact of Tuberculosis Infection on HIV-1 Antibody Response...

Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More